Citations (5)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Agnete Nielsen, Peter Bo Poulsen, Lars Dybro, Bitten Kloster, Anette Lorentzen, Jens Olsen & Thomas Kümler. (2019) Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting. Journal of Medical Economics 22:12, pages 1321-1327.
Read now
Read now
Articles from other publishers (4)
Lucca Katrine Sciera, Lars Frost, Lars Dybro & Peter Bo Poulsen. (2022) The cost-effectiveness of one-time opportunistic screening for atrial fibrillation in different age cohorts of inhabitants in Denmark aged 65 years and above: a Markov modelled analysis. European Heart Journal - Quality of Care and Clinical Outcomes 8:2, pages 177-186.
Crossref
Crossref
Swee Kee Tan, Wan Lin Looi & Hui Yee Yeo. (2020) Estimation of direct medical costs of warfarin, dabigatran and rivaroxaban treatments in non‐valvular atrial fibrillation patients in a tertiary public hospital, Malaysia. Journal of Pharmacy Practice and Research 50:5, pages 406-412.
Crossref
Crossref
Nina Gustafsson, Peter Bo Poulsen, Sandra Elkjær Stallknecht, Lars Dybro & Søren Paaske Johnsen. (2020) Societal costs of venous thromboembolism and subsequent major bleeding events: a national register-based study. European Heart Journal - Quality of Care and Clinical Outcomes 6:2, pages 130-137.
Crossref
Crossref
Amber L Martin, Alessandra G Reeves, Samantha E Berger, Manuela Di Fusco, Gail D Wygant, Mirko Savone, Kassandra Snook, Mina Nejati & Tereza Lanitis. (2019) Systematic review of societal costs associated with stroke, bleeding and monitoring in atrial fibrillation. Journal of Comparative Effectiveness Research 8:14, pages 1147-1166.
Crossref
Crossref